Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_2
3
75%
Ph phase_3
1
25%

Phase Distribution

0

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
3(75.0%)
Phase 3Large-scale testing
1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

25.0%

1 of 4 finished

Non-Completion Rate

75.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(1)
Terminated(3)

Detailed Status

Withdrawn2
Terminated1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 23 (75.0%)
Phase 31 (25.0%)

Trials by Status

withdrawn250%
terminated125%
completed125%

Recent Activity

0 active trials
Showing 4 of 4
withdrawnphase_2

Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma

NCT00006669
completedphase_3

Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma

NCT00053768
withdrawnphase_2

Rituximab and Combination Chemotherapy With or Without Bleomycin Sulfate in Treating Patients With Primary Mediastinal Large B-Cell Lymphoma

NCT00983944
terminatedphase_2

Combination Chemotherapy With or Without Etoposide in Treating Older Patients With Non-Hodgkin's Lymphoma

NCT00060385

Clinical Trials (4)

Showing 4 of 4 trials
NCT00006669Phase 2

Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma

Withdrawn
NCT00053768Phase 3

Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma

Completed
NCT00983944Phase 2

Rituximab and Combination Chemotherapy With or Without Bleomycin Sulfate in Treating Patients With Primary Mediastinal Large B-Cell Lymphoma

Withdrawn
NCT00060385Phase 2

Combination Chemotherapy With or Without Etoposide in Treating Older Patients With Non-Hodgkin's Lymphoma

Terminated

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4